Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Elevation Oncology ( (ELEV) ) is now available.
On January 29, 2025, Elevation Oncology announced the resignation of Chief Scientific Officer, Dr. David Dornan, effective February 17, 2025, as he pursues another opportunity. While Dr. Dornan’s departure is amicable, he will continue to aid in the transition in a consulting role, ensuring a smooth shift in responsibilities.
More about Elevation Oncology
Elevation Oncology, Inc. operates in the biotechnology sector, focusing on the development of precision therapies for cancer treatment.
YTD Price Performance: 11.00%
Average Trading Volume: 2,049,363
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $39.41M
For detailed information about ELEV stock, go to TipRanks’ Stock Analysis page.